Shares of Lyell Immunopharma, Inc. (LYEL) are up more than 13% Monday morning at $8.60.
The company today presented first-in-human Phase 1 study design of its ROR1-targeted CAR T-cell therapy LYL797 for the treatment of solid tumors, at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
"This first-in-human Phase 1 trial is designed to provide important data on the potential of Lyell's innovative reprogramming technologies to endow T cells with durable anti-tumor functionality," stated Tina Albertson, chief medical officer of Lyell.
LYEL has been trading in the range of $3.57-$17.75in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.